

HALOZYME THERAPEUTICS INC

Form 8-K

May 10, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of the  
Securities Exchange Act of 1934  
Date of report (Date of earliest event reported): May 10, 2006  
HALOZYME THERAPEUTICS, INC.  
(Exact name of registrant as specified in its charter)**

|  |  |                                      |
|--|--|--------------------------------------|
| Nevada   | 000-49616  | 88-0488686                           |
| (State or other jurisdiction<br>of incorporation)              | (Commission<br>File Number)  | (IRS Employer<br>Identification No.) |
| 11588 Sorrento Valley Road, Suite 17, San Diego,<br>California |  | 92121                                |
| (Address of principal executive offices)                       |  | (Zip Code)                           |
|  | Registrant's telephone number, including area code: (858) 794-8889 |                                      |
|  | Not Applicable   |                                      |

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents**

**Item 2.02. Results of Operations and Financial Condition.**

On May 10, 2006, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the three months ended March 31, 2006. The press release is attached as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

| Exhibit No. | Description                      |
|-------------|----------------------------------|
| 99.1        | Press Release dated May 10, 2006 |

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

May 10, 2006

By: /s/ David A. Ramsay

**David A. Ramsay**

**Secretary and Chief Financial Officer**